There is a well-known meta-analysis that indicates that NSCLC patients with KRAS mutations had a worse survival rate (hazard ratio, 1.59; 95% CI: 1.16–1.56) [15]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.